Patents by Inventor Venkataramana Naidu
Venkataramana Naidu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11433058Abstract: An oral solid non-pulsatile 24 hours prolonged-release composition including an amount of betahistine, or of a pharmaceutically acceptable salt thereof, equivalent to 48 mg of betahistine dihydrochloride, together with one or more pharmaceutically acceptable excipients or carriers, wherein the composition exhibits a dissolution profile according to which: up to 30% by weight of betahistine is dissolved in 1 hour; from 35% to 45% by weight of betahistine is dissolved in 2 hours; from 46% to 60% by weight of betahistine is dissolved in 4 hours; from 61% to 80% by weight of betahistine is dissolved in 8 hours; from 81% to 97% by weight of betahistine is dissolved in 16 hours; and from 98% to 100% by weight of betahistine is dissolved in 24 hours. It also relates to the treatment of a vestibular disease or condition, more particularly in the treatment of Ménière's disease.Type: GrantFiled: July 16, 2018Date of Patent: September 6, 2022Assignee: INTAS PHARMACEUTICALS LTD.Inventors: Himanshukumar Dasharathlal Patel, Vinod Purushottam Dube, Venkataramana Naidu, Sunil Shantwan Borude
-
Publication number: 20220273646Abstract: A stable pharmaceutical composition of temozolomide for oral administration. The pharmaceutical composition is in the form of powder for oral suspension, wherein the said powder is reconstituted with a liquid vehicle just before administration. Further the invention relates to process for the preparation of said pharmaceutical composition and its packaging in individual doses.Type: ApplicationFiled: July 16, 2020Publication date: September 1, 2022Applicant: INTAS PHARMACEUTICALS LTD.Inventors: Jwalant Vijaybhai DESAI, Mayank SAXENA, Ashutosh JAMLOKI, Venkataramana NAIDU
-
Publication number: 20220273645Abstract: A lactose free, stable pharmaceutical composition having naltrexone or its pharmaceutically acceptable salt thereof. Also disclosed is a process for the preparation of the composition and its use in a method for the treatment of Crohn's disease.Type: ApplicationFiled: July 7, 2020Publication date: September 1, 2022Applicant: INTAS PHARMACEUTICALS LTD.Inventors: Alkeshkumar Narayanbhai PATEL, Manish Mavjibhai PATEL, Manishkumar Jayantibhai CHAUHAN, Venkataramana NAIDU
-
Publication number: 20220273652Abstract: A multilayer, pharmaceutical composition having a fixed dose combination of rosuvastatin or a pharmaceutically acceptable salt thereof and fenofibrate or a pharmaceutically acceptable salt thereof, wherein the fenofibrate or the pharmaceutically acceptable salt thereof and the rosuvastatin or the pharmaceutically acceptable salt thereof are present in separate layers, namely a fenofibrate layer and a rosuvastatin layer, wherein fenofibrate and rosuvastatin are immediately released from the fenofibrate layer and the rosuvastatin layer, respectively, and wherein the fenofibrate layer having micronized fenofibrate. A process for the preparation of the composition is also disclosed.Type: ApplicationFiled: July 30, 2020Publication date: September 1, 2022Applicant: INTAS PHARMACEUTICALS LTD.Inventors: Hitendra Netlal RAHANGDALE, Narendra Bhagwatbhai PRAJAPATI, Satyavan Shivajirao DHAVALE, Venkataramana NAIDU
-
Publication number: 20220265688Abstract: A stable oral composition for cyclophosphamide or its pharmaceutically acceptable salt. The composition for cyclophosphamide can be in the form of powder for oral solution, which can provide an improved stability, ease for reconstitution, and better palatability suitable for pediatric patients. Also disclosed is a process for preparation of the powder for oral solution of cyclophosphamide.Type: ApplicationFiled: July 9, 2020Publication date: August 25, 2022Applicant: INTAS PHARMACEUTICALS LTD.Inventors: Venkataramana NAIDU, Jwalant Vijaybhai DESAI, Mayank SAXENA, Ashutosh JAMLOKI
-
Publication number: 20220265653Abstract: A pharmaceutical composition having imatinib or its pharmaceutically acceptable salt thereof and one or more pharmaceutical acceptable excipients in powder form, which can be reconstituted with a diluent just before administration. Also disclosed is a process for the preparation of the composition and its use in a method for the treatment of cancer in pediatric patients.Type: ApplicationFiled: July 15, 2020Publication date: August 25, 2022Applicant: INTAS PHARMACEUTICALS LTD.Inventors: Jwalant Vijaybhai DESAI, Mayank SAXENA, Ashutosh JAMLOKI, Venkataramana NAIDU
-
Publication number: 20220226368Abstract: Essentially sodium-free effervescent solid pharmaceutical compositions The present invention relates to an effervescent solid pharmaceutical composition, which is essentially free of sodium content, comprising: a therapeutically effective amount of an active pharmaceutical ingredient; one or more pharmaceutically acceptable alkaline earth metal carbonates or hydrogencarbonates in an amount from 1 to 31% by weight of the composition; and one or more pharmaceutically acceptable acids, pharmaceutically acceptable acid salts, or alternatively, a mixture thereof, in an amount from 2 to 62% by weight of the composition; together with one or more pharmaceutically acceptable excipients or carriers; wherein, the total content of the ion sodium in the effervescent solid pharmaceutical composition is equal to or lower than 1 mmol. It also relates to processes for its preparation and its use in therapy.Type: ApplicationFiled: March 29, 2022Publication date: July 21, 2022Inventors: José María SUÑÉ NEGRE, Manuel ROIG CARRERAS, Marc SUÑÉ POU, Anna NARDI RICART, Xavier FORMOSA MÁRQUEZ, Manishkumar Jayantibhai CHAUHAN, Venkataramana NAIDU, Manish Mavjibhai PATEL
-
Publication number: 20210161871Abstract: An oral solid non-pulsatile 24 hours prolonged-release composition including an amount of betahistine, or of a pharmaceutically acceptable salt thereof, equivalent to 48 mg of betahistine dihydrochloride, together with one or more pharmaceutically acceptable excipients or carriers, wherein the composition exhibits a dissolution profile according to which: up to 30% by weight of betahistine is dissolved in 1 hour; from 35% to 45% by weight of betahistine is dissolved in 2 hours; from 46% to 60% by weight of betahistine is dissolved in 4 hours; from 61% to 80% by weight of betahistine is dissolved in 8 hours; from 81% to 97% by weight of betahistine is dissolved in 16 hours; and from 98% to 100% by weight of betahistine is dissolved in 24 hours. It also relates to the treatment of a vestibular disease or condition, more particularly in the treatment of Ménière's disease.Type: ApplicationFiled: July 16, 2018Publication date: June 3, 2021Applicant: INTAS PHARMACEUTICALS LTD.Inventors: Himanshukumar Dasharathlal PATEL, Vinod Purushottam DUBE, Venkataramana NAIDU, Sunil Shantwan BORUDE
-
Publication number: 20210137917Abstract: The present invention provides a pharmaceutical composition comprising suspension of Nintedanib esylate and lauroyl polyoxyl-6 glyceride or hydrogenated vegetable oil, in a soft gelatin capsule; wherein lauroyl polyoxyl-6 glyceride or hydrogenated vegetable oil are used as a thickener. Further, the present invention provides a process for preparation of pharmaceutical composition comprising suspension of Nintedanib esylate and lauroyl polyoxyl-6 glyceride or hydrogenated vegetable oil, in a soft gelatin capsule.Type: ApplicationFiled: April 8, 2019Publication date: May 13, 2021Inventors: Nilesh Bhagwat TELI, Pradosh Ranjan SAHOO, Sunil Shantwan BORUDE, Venkataramana NAIDU
-
Patent number: 9566299Abstract: The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof comprising mixture of water and organic solvent(s) and/or less than of about 10% of plasticizing agent in the coating composition. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises mixture of water and organic solvent(s) and less than of about 10% of plasticizing agent in coating. The invention also includes process of preparing such composition.Type: GrantFiled: February 5, 2014Date of Patent: February 14, 2017Assignee: WOCKHARDT LIMITEDInventors: Girish Kumar Jain, Venkataramana Naidu, Abdul Rehman Khan, Amar Agarwal, Srikanth Pattipati
-
Publication number: 20150374713Abstract: The present invention relates to a stable pharmaceutical composition of amiodipine and benazepril or salts thereof. In particular, the invention relates to a stable pharmaceutical composition comprising at least one amiodipine component and at least two benazepril components in which physical contact between amiodipine and benazepril components is limited. The invention also includes a process of preparing such compositions and method of treating hypertension by administering the composition to a patient in need thereof.Type: ApplicationFiled: February 5, 2014Publication date: December 31, 2015Applicant: WOCKHARDT LIMITEDInventors: Girish Kumar JAIN, Venkataramana NAIDU, Pankaj Umakant ATTARDE
-
Publication number: 20150374744Abstract: The present invention relates to an oral pharmaceutical composition of aliphatic amine polymer or salts thereof comprising mixture of water and organic solvent(s) and/or less than of about 10% of plasticizing agent in the coating composition. In particular, present invention relates to a coated pharmaceutical composition of aliphatic amine polymer or salt thereof which comprises mixture of water and organic solvent(s) and less than of about 10% of plasticizing agent in coating. The invention also includes process of preparing such composition.Type: ApplicationFiled: February 5, 2014Publication date: December 31, 2015Inventors: Girish Kumar JAIN, Venkataramana NAIDU, Abdul Rehman KHAN, Amar AGARWAL, Srikanth PATTIPATI
-
Publication number: 20150374688Abstract: The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a multilayered coated pharmaceutical composition comprising at least two compartments of metformin or salts thereof exhibiting immediate and extended release and at least one compartment of sitagliptin and metformin or salts thereof exhibiting immediate release. The invention also includes process of preparing such compositions and method of use of such compositions for treating type II diabetes.Type: ApplicationFiled: March 21, 2014Publication date: December 31, 2015Inventors: Girish Kumar JAIN, Venkataramana NAIDU, Atul PATIL
-
Publication number: 20150366863Abstract: The present invention provides solid oral pharmaceutical compositions comprising combination of metformin and sitagliptin or salts thereof. In particular, the present invention relates to a pharmaceutical composition comprising metformin and sitagliptin or salts thereof which is glidant and/or surface active agent. The invention also includes process of preparing such compositions and method of use of such compositions for treating type II diabetes.Type: ApplicationFiled: March 24, 2014Publication date: December 24, 2015Inventors: Girish Kumar JAIN, Venkataramana NAIDU, Atul PATIL
-
Publication number: 20150250734Abstract: The present invention refers to a stable pharmaceutical composition of saxagliptin or salts thereof. In particular, the invention relates to stable comprises a core and two or more layers coated on the core, wherein the composition or the inner first coat is free of polyvinyl alcohol. Such composition of saxagliptin may exhibit relatively improved storage stability and particularly, levels of degradants in the formulation during storage can be effectively controlled. The invention also includes a process of preparing such compositions and method of treating type-II diabetes mellitus by administering the composition to a patient in need thereof.Type: ApplicationFiled: May 3, 2013Publication date: September 10, 2015Inventors: Girish Kumar Jain, Venkataramana Naidu, Balasaheb Parshuram Wagh, Vijay Suggala